BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gaborit N, Lindzen M, Yarden Y. Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3. Hum Vaccin Immunother 2016;12:576-92. [PMID: 26529100 DOI: 10.1080/21645515.2015.1102809] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Barrientos-Robledo SG, Cebada-Ruiz JA, Rodríguez-Alba JC, Baltierra-Uribe SL, Díaz Y Orea MA, Romero-Ramírez H. CD38 a biomarker and therapeutic target in non-hematopoietic tumors. Biomark Med 2022. [PMID: 35195042 DOI: 10.2217/bmm-2021-0575] [Reference Citation Analysis]
2 Hassani D, Jeddi-Tehrani M, Yousefi P, Mansouri-Fard S, Mobini M, Ahmadi-Zare H, Golsaz-Shirazi F, Amiri MM, Shokri F. Differential tumor inhibitory effects induced by HER3 extracellular subdomain-specific mouse monoclonal antibodies. Cancer Chemother Pharmacol 2022. [PMID: 35079876 DOI: 10.1007/s00280-021-04390-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ghalamfarsa F, Khatami SH, Vakili O, Taheri-Anganeh M, Tajbakhsh A, Savardashtaki A, Fazli Y, Uonaki LR, Shabaninejad Z, Movahedpour A, Ghalamfarsa G. Bispecific antibodies in colorectal cancer therapy: recent insights and emerging concepts. Immunotherapy 2021;13:1355-67. [PMID: 34641708 DOI: 10.2217/imt-2021-0107] [Reference Citation Analysis]
4 Rathore M, Wright M, Bhattacharya R, Fan F, Vaziri-gohar A, Winter J, Wang Z, Markowitz SD, Willis J, Ellis LM, Wang R. Liver Endothelium Promotes HER3-mediated Cell Survival in KRAS Wild-type and Mutant Colorectal Cancer Cells.. [DOI: 10.1101/2021.04.27.441690] [Reference Citation Analysis]
5 Capone E, Lattanzio R, Gasparri F, Orsini P, Rossi C, Iacobelli V, De Laurenzi V, Natali PG, Valsasina B, Iacobelli S, Sala G. EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors. Pharmaceutics 2021;13:483. [PMID: 33918158 DOI: 10.3390/pharmaceutics13040483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Ptáková N, Martínek P, Holubec L, Janovský V, Vančurová J, Grossmann P, Navarro PA, Rodriguez Moreno JF, Alaghehbandan R, Hes O, Májek O, Pešek M, Michal M, Ondič O. Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database. Genes Chromosomes Cancer 2021;60:474-81. [PMID: 33583086 DOI: 10.1002/gcc.22942] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
7 Wu L, Islam MR, Lee J, Takase H, Guo S, Andrews AM, Buzhdygan TP, Mathew J, Li W, Arai K, Lo EH, Ramirez SH, Lok J. ErbB3 is a critical regulator of cytoskeletal dynamics in brain microvascular endothelial cells: Implications for vascular remodeling and blood brain barrier modulation. J Cereb Blood Flow Metab 2021;41:2242-55. [PMID: 33583260 DOI: 10.1177/0271678X20984976] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
8 Biancur DE, Kapner KS, Yamamoto K, Banh RS, Neggers JE, Sohn ASW, Wu W, Manguso RT, Brown A, Root DE, Aguirre AJ, Kimmelman AC. Functional Genomics Identifies Metabolic Vulnerabilities in Pancreatic Cancer. Cell Metab 2021;33:199-210.e8. [PMID: 33152323 DOI: 10.1016/j.cmet.2020.10.018] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
9 Hafeez U, Parslow AC, Gan HK, Scott AM. New insights into ErbB3 function and therapeutic targeting in cancer. Expert Rev Anticancer Ther 2020;20:1057-74. [PMID: 32981377 DOI: 10.1080/14737140.2020.1829485] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
10 Kumar R, George B, Campbell MR, Verma N, Paul AM, Melo-Alvim C, Ribeiro L, Pillai MR, da Costa LM, Moasser MM. HER family in cancer progression: From discovery to 2020 and beyond. Adv Cancer Res 2020;147:109-60. [PMID: 32593399 DOI: 10.1016/bs.acr.2020.04.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
11 Gandullo-Sánchez L, Capone E, Ocaña A, Iacobelli S, Sala G, Pandiella A. HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies. EMBO Mol Med 2020;12:e11498. [PMID: 32329582 DOI: 10.15252/emmm.201911498] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
12 Kim H, Choi JY, Rah YC, Ahn JC, Kim H, Jeong WJ, Ahn SH. ErbB3, a possible prognostic factor of head and neck squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol 2020;129:377-87. [PMID: 32081558 DOI: 10.1016/j.oooo.2019.12.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Bourillon L, Demontoy S, Lenglet A, Zampieri A, Fraisse J, Jarlier M, Boissière-Michot F, Perrochia H, Rathat G, Garambois V, Bonnefoy N, Michaud HA, Chardès T, Tosi D, Pèlegrin A, Azria D, Larbouret C, Bourgier C. Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer Cells. Int J Radiat Oncol Biol Phys 2020;106:1039-51. [PMID: 31959545 DOI: 10.1016/j.ijrobp.2019.12.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
14 Pan X, Lin P, Feng F, Li J, Li Y, Dai W, Hu B, Yang X, Fan J, Li H, Li Y. Comparison of immune profiles between hepatocellular carcinoma subtypes. Biophys Rep 2020;6:19-32. [DOI: 10.1007/s41048-019-00102-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Kiavue N, Cabel L, Melaabi S, Bataillon G, Callens C, Lerebours F, Pierga J, Bidard F. ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics. Oncogene 2020;39:487-502. [DOI: 10.1038/s41388-019-1001-5] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 15.0] [Reference Citation Analysis]
16 Zhan W, Liao X, Li L, Chen Z, Tian T, Yu L, Chen Z. In vitro mitochondrial-targeted antioxidant peptide induces apoptosis in cancer cells. Onco Targets Ther 2019;12:7297-306. [PMID: 31686844 DOI: 10.2147/OTT.S207640] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
17 Marrocco I, Romaniello D, Yarden Y. Cancer Immunotherapy: The Dawn of Antibody Cocktails. Methods Mol Biol 2019;1904:11-51. [PMID: 30539465 DOI: 10.1007/978-1-4939-8958-4_2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
18 Groner Y, Sachs P, Lotem J. Leo Sachs. 14 October 1924—12 December 2013. Biogr Mems Fell R Soc 2019;66:355-375. [DOI: 10.1098/rsbm.2018.0027] [Reference Citation Analysis]
19 Saez-ibanez AR, Scheffler JM, Terabayashi T, Daubel N, Makinen T, Idevall-hagren O, Ferby I. Ligand-independent role of ErbB3 in endocytic recycling.. [DOI: 10.1101/575449] [Reference Citation Analysis]
20 Menke-van der Houven van Oordt CW, McGeoch A, Bergstrom M, McSherry I, Smith DA, Cleveland M, Al-Azzam W, Chen L, Verheul H, Hoekstra OS, Vugts DJ, Freedman I, Huisman M, Matheny C, van Dongen G, Zhang S. Immuno-PET Imaging to Assess Target Engagement: Experience from 89Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors. J Nucl Med 2019;60:902-9. [PMID: 30733323 DOI: 10.2967/jnumed.118.214726] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 8.7] [Reference Citation Analysis]
21 Nevenzal H, Noach-Hirsh M, Skornik-Bustan O, Brio L, Barbiro-Michaely E, Glick Y, Avrahami D, Lahmi R, Tzur A, Gerber D. A high-throughput integrated microfluidics method enables tyrosine autophosphorylation discovery. Commun Biol 2019;2:42. [PMID: 30729180 DOI: 10.1038/s42003-019-0286-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
22 Mancini M, Gal H, Gaborit N, Mazzeo L, Romaniello D, Salame TM, Lindzen M, Mahlknecht G, Enuka Y, Burton DG, Roth L, Noronha A, Marrocco I, Adreka D, Altstadter RE, Bousquet E, Downward J, Maraver A, Krizhanovsky V, Yarden Y. An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors. EMBO Mol Med 2018;10:294-308. [PMID: 29212784 DOI: 10.15252/emmm.201708076] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
23 Turowec JP, Lau EWT, Wang X, Brown KR, Fellouse FA, Jawanda KK, Pan J, Moffat J, Sidhu SS. Functional genomic characterization of a synthetic anti-HER3 antibody reveals a role for ubiquitination by RNF41 in the anti-proliferative response. J Biol Chem 2019;294:1396-409. [PMID: 30523157 DOI: 10.1074/jbc.RA118.004420] [Reference Citation Analysis]
24 Rinne SS, Leitao CD, Mitran B, Bass TZ, Andersson KG, Tolmachev V, Ståhl S, Löfblom J, Orlova A. Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111. Sci Rep 2019;9:655. [PMID: 30679757 DOI: 10.1038/s41598-018-36827-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
25 Luhtala S, Staff S, Kallioniemi A, Tanner M, Isola J. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer. BMC Cancer 2018;18:1045. [PMID: 30367623 DOI: 10.1186/s12885-018-4917-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
26 Wang R, Bhattacharya R, Ye X, Fan F, Boulbes DR, Ellis LM. Endothelial Cells Promote Colorectal Cancer Cell Survival by Activating the HER3-AKT Pathway in a Paracrine Fashion. Mol Cancer Res. 2019;17:20-29. [PMID: 30131447 DOI: 10.1158/1541-7786.mcr-18-0341] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
27 Capone E, Lamolinara A, D'agostino D, Rossi C, De Laurenzi V, Iezzi M, Iacobelli S, Sala G. EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma. Journal of Controlled Release 2018;277:48-56. [DOI: 10.1016/j.jconrel.2018.03.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
28 Kampa R, Bednarek I, Sypniewski D. Monoclonal antibodies in regulation of signal transduction of Epidermal Growth Factor Receptor (EGFR) pathway in cancer cells. Ann Acad Med Siles 2018;72:12-20. [DOI: 10.18794/aams/74664] [Reference Citation Analysis]
29 Booth L, Roberts JL, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Poklepovic A, Dent P. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells. Cancer Biol Ther 2018;19:239-47. [PMID: 29333953 DOI: 10.1080/15384047.2018.1423927] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
30 Le Clorennec C, Lazrek Y, Dubreuil O, Larbouret C, Poul MA, Mondon P, Melino G, Pèlegrin A, Chardès T. The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation. Oncotarget 2016;7:37013-29. [PMID: 27203743 DOI: 10.18632/oncotarget.9455] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
31 Wadhwa B, Makhdoomi U, Vishwakarma R, Malik F. Protein kinase B: emerging mechanisms of isoform-specific regulation of cellular signaling in cancer. Anticancer Drugs 2017;28:569-80. [PMID: 28379898 DOI: 10.1097/CAD.0000000000000496] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
32 Capone E, Giansanti F, Ponziani S, Lamolinara A, Iezzi M, Cimini A, Angelucci F, Sorda R, Laurenzi V, Natali PG, Ippoliti R, Iacobelli S, Sala G. EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma. Oncotarget 2017;8:95412-24. [PMID: 29221137 DOI: 10.18632/oncotarget.20728] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
33 Schmitt LC, Rau A, Seifert O, Honer J, Hutt M, Schmid S, Zantow J, Hust M, Dübel S, Olayioye MA, Kontermann RE. Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV. MAbs 2017;9:831-43. [PMID: 28421882 DOI: 10.1080/19420862.2017.1319023] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
34 Kennedy SP, Hastings JF, Han JZ, Croucher DR. The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor Family. Front Cell Dev Biol 2016;4:88. [PMID: 27597943 DOI: 10.3389/fcell.2016.00088] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
35 Lopez-Haber C, Barrio-Real L, Casado-Medrano V, Kazanietz MG. Heregulin/ErbB3 Signaling Enhances CXCR4-Driven Rac1 Activation and Breast Cancer Cell Motility via Hypoxia-Inducible Factor 1α. Mol Cell Biol 2016;36:2011-26. [PMID: 27185877 DOI: 10.1128/MCB.00180-16] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
36 Tang HM, Kuay KT, Koh PF, Asad M, Tan TZ, Chung VY, Lee SC, Thiery JP, Huang RJ. An epithelial marker promoter induction screen identifies histone deacetylase inhibitors to restore epithelial differentiation and abolishes anchorage independence growth in cancers. Cell Death Discov 2016;2:16041. [PMID: 27551531 DOI: 10.1038/cddiscovery.2016.41] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]